Indivior Pharmaceuticals, Inc.INDVEarnings & Financial Report
Nasdaq
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
NextMar 13, 2026
INDV Q3 2026 Key Financial Metrics
Revenue
$314.0M
Gross Profit
$230.0M
Operating Profit
$43.0M
Net Profit
$42.0M
Gross Margin
73.2%
Operating Margin
13.7%
Net Margin
13.4%
YoY Growth
N/A
EPS
$0.33
Financial Flow
Indivior Pharmaceuticals, Inc. Q3 2026 Financial Summary
Indivior Pharmaceuticals, Inc. reported revenue of $314.0M for Q3 2026, with a net profit of $42.0M (13.4% margin). Cost of goods sold was $84.0M, operating expenses totaled $187.0M.
Key Financial Metrics
| Total Revenue | $314.0M |
|---|---|
| Net Profit | $42.0M |
| Gross Margin | 73.2% |
| Operating Margin | 13.7% |
| Report Period | Q3 2026 |
Income Statement
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| Revenue | $284.0M | $266.0M | $302.0M | $314.0M |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| Assets | N/A | $1.38B | $1.45B | $1.42B |
| Liabilities | N/A | $1.66B | $1.71B | $1.62B |
| Equity | $-161.0M | $-285.0M | $-257.0M | $-207.0M |
Cash Flow
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| Operating CF | $-37.0M | $75.0M | $158.0M | $-39.0M |